Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials

OBJECTIVES: The single‐tablet regimen rilpivirine, emtricitabine and tenofovir alafenamide (RPV/FTC/TAF) for treatment of HIV‐1‐infected adults was approved based on bioequivalence. We assessed the clinical efficacy, safety and tolerability of switching to RPV/FTC/TAF from either RPV/FTC/tenofovir d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagins, D, Orkin, C, Daar, ES, Mills, A, Brinson, C, DeJesus, E, Post, FA, Morales‐Ramirez, J, Thompson, M, Osiyemi, O, Rashbaum, B, Stellbrink, H‐J, Martorell, C, Liu, H, Liu, Y‐P, Porter, D, Collins, SE, SenGupta, D, Das, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221083/
https://www.ncbi.nlm.nih.gov/pubmed/30101539
http://dx.doi.org/10.1111/hiv.12664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221083/
https://www.ncbi.nlm.nih.gov/pubmed/30101539
http://dx.doi.org/10.1111/hiv.12664

Ejemplares similares